Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clazakizumab dose-ranging study in TNF inhibitor inadequate responder rheumatoid arthritis
2013-003780-65Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Clazakizumab + methotrexate with Placebo + methotrexate (2 arms). Primary endpoint: Disease Activity Score in 28 joints - C-reactive protein (DAS28-CRP) change from baseline at Week 12. Started Dec 2013; status: completed.
02
Drugs
clazakizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2013-003780-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003780-65.